Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of ISIS 681257 in hyperlipoproteinemia(a) with established cardiovascular disease
NL-OMON47033Phase 2Active, not recruiting
- Sponsor
- Akcea Therapeutics, Inc.
- Start
- Jul 2017
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperlipoproteinemia and cardiac morbidity comparing ISIS 681257 with Placebo (2 arms). Primary endpoint: Percent change in lipoprotein(a) from baseline. Started Jul 2017; status: active, not recruiting.
02
Drugs
pelacarsen
03
Conditions
hyperlipoproteinemiacardiac morbidity
Beyond the preview
Go deeper on NL-OMON47033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47033.